Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (45)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Koch, J.-A.
Right arrow Articles by Mödder, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koch, J.-A.
Right arrow Articles by Mödder, U.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 43-49
© 2000 European Renal Association-European Dialysis and Transplant Association

Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media?

Jens-Albrecht Koch1, Jörg Plum2, Bernd Grabensee2, Ulrich Mödder and PGE1 Study Group1

1 Department of Diagnostic Radiology and 2 Department of Nephrology and Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany

Correspondence and offprint requests to: Jens-Albrecht Koch, MD, Department of Diagnostic Radiology, Heinrich-Heine-University, Moorenstraße 5, D-40225 Düsseldorf, Germany.

Background. Acute renal failure following the administration of radiocontrast media (RCM) is a complication found especially in patients with impaired renal function. Within the limits of a pilot study, the objective was to (a) show the effectiveness and compatibility of prostaglandin E1 (PGE1=Alprostadil) in preventing acute renal failure in patients with elevated levels of serum creatinine and (b) to identify the most appropriate PGE1-dose.

Methods. 130 patients with renal impairment (serum creatinine >=1.5 mg/dl) were included in the study prior to intravascular RCM injection. The patients received one of three different doses of PGE1 (10, 20, or 40 ng/kg bodyweight/min) or placebo (physiologic sodium chloride solution) intravenously over a time period of 6 h (beginning 1 h prior to RCM application). Serum creatinine was measured 12, 24, and 48 h post RCM-application and creatinine clearance was determined with two 12 h collection periods, as well as one 24 h collection within 48 h post RCM administration. Adverse events during PGE1 administration were recorded.

Results. In the placebo group, the mean elevation of serum creatinine was markedly higher (0.72 mg/dl) 48 h after RCM administration compared with the three PGE1 groups (0.3 mg/dl in the 10 ng/kg/min group, 0.12 mg in the 20 ng/kg/min group, and 0.29 mg/dl in the 40 ng/kg/min group). No clinically relevant changes were seen regarding the creatinine clearance in the four groups examined.

Conclusions. Results from this pilot-study suggest that intravenous PGE1 may be used efficaciously and safely to prevent RCM-induced renal dysfunction in patients with pre-existing impaired renal function.

Keywords: contrast media; renal function; prostaglandin E1


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
A. Feliciani, M. A. Riva, S. Zerbi, P. Ruggiero, A. R. Plati, G. Cozzi, and L. A. Pedrini
New strategies in haemodiafiltration (HDF): prospective comparative analysis between on-line mixed HDF and mid-dilution HDF
Nephrol. Dial. Transplant., March 8, 2007; (2007) gfm023v1.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
D. Schiesser, I. Binet, D. Tsinalis, M. Dickenmann, G. Keusch, M. Schmidli, P. M. Ambuhl, L. Luthi, and R. P. Wuthrich
Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients
Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2841 - 2845.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
N. Pannu, N. Wiebe, M. Tonelli, and for the Alberta Kidney Disease Network
Prophylaxis Strategies for Contrast-Induced Nephropathy
JAMA, June 21, 2006; 295(23): 2765 - 2779.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
W. Huber, F. Eckel, M. Hennig, H. Rosenbrock, A. Wacker, D. Saur, A. Sennefelder, R. Hennico, C. Schenk, A. Meining, et al.
Prophylaxis of Contrast Material-induced Nephropathy in Patients in Intensive Care: Acetylcysteine, Theophylline, or Both? A Randomized Study.
Radiology, June 1, 2006; 239(3): 793 - 804.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
J. W. Sear
Kidney dysfunction in the postoperative period
Br. J. Anaesth., July 1, 2005; 95(1): 20 - 32.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
A. S. Gami and V. D. Garovic
Contrast Nephropathy After Coronary Angiography
Mayo Clin. Proc., February 1, 2004; 79(2): 211 - 219.
[Abstract] [PDF]


Home page
RadiologyHome page
R. Tello, W. Huber, W. Weiss, and K. Ilgmann
Intrarenal Kinetics: Effect of Adenosine and Theophylline * Dr Huber and colleagues respond:
Radiology, February 1, 2003; 226(2): 596 - 597.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
V. L. M. Esnault
Radiocontrast media-induced nephrotoxicity in patients with renal failure: rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonists
Nephrol. Dial. Transplant., August 1, 2002; 17(8): 1362 - 1364.
[Full Text] [PDF]


Home page
RadiologyHome page
W. Huber, K. Ilgmann, M. Page, M. Hennig, U. Schweigart, B. Jeschke, L. Lutilsky, W. Weiss, H. Salmhofer, and M. Classen
Effect of Theophylline on Contrast Material-induced Nephropathy in Patients with Chronic Renal Insufficiency: Controlled, Randomized, Double-blinded Study
Radiology, June 1, 2002; 223(3): 772 - 779.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
C. Mueller, G. Buerkle, H. J. Buettner, J. Petersen, A. P. Perruchoud, U. Eriksson, S. Marsch, and H. Roskamm
Prevention of Contrast Media-Associated Nephropathy: Randomized Comparison of 2 Hydration Regimens in 1620 Patients Undergoing Coronary Angioplasty
Arch Intern Med, February 11, 2002; 162(3): 329 - 336.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
C. A. BLOCK and H. L. MANNING
Prevention of Acute Renal Failure in the Critically Ill
Am. J. Respir. Crit. Care Med., February 1, 2002; 165(3): 320 - 324.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
G. Lonnemann and K. M. Koch
{beta}2-Microglobulin Amyloidosis: Effects of Ultrapure Dialysate and Type of Dialyzer Membrane
J. Am. Soc. Nephrol., January 1, 2002; 13(90001): S72 - 77.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
F. Locatelli, L. D. Vecchio, and S. Andrulli
The modality of dialysis treatment: does it influence the response to erythropoietin treatment?
Nephrol. Dial. Transplant., October 1, 2001; 16(10): 1971 - 1974.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
N. LAMEIRE and R. VANHOLDER
Pathophysiologic Features and Prevention of Human and Experimental Acute Tubular Necrosis
J. Am. Soc. Nephrol., February 1, 2001; 12(90001): S20 - S32.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
R. A. WARD, B. SCHMIDT, J. HULLIN, G. F. HILLEBRAND, and W. SAMTLEBEN
A Comparison of On-Line Hemodiafiltration and High-Flux Hemodialysis: A Prospective Clinical Study
J. Am. Soc. Nephrol., December 1, 2000; 11(12): 2344 - 2350.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.